The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after the US Food and Drug Administration granted it a breakthrough de
There are concerns that launch of Teva’s migraine drug may be delayed because of issues uncovered by the FDA at a manufacturing plant run by South Korea’s Celltrion.
Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.
Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre
Eli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the biotech to the leading pack of the migraine cure race, among Allergan, Amgen a
